Show simple item record

dc.contributor.authorGelderblom, H
dc.contributor.authorJones, RL
dc.contributor.authorGeorge, S
dc.contributor.authorValverde, MC
dc.contributor.authorBenson, C
dc.contributor.authorJean-Yves, B
dc.contributor.authorRenouf, DJ
dc.contributor.authorDoi, T
dc.contributor.authorLe, CA
dc.contributor.authorLeahy, Michael G
dc.contributor.authorHertle, S
dc.contributor.authorAimone, P
dc.contributor.authorBrandt, U
dc.contributor.authorSchffski, P
dc.date.accessioned2020-03-27T09:27:59Z
dc.date.available2020-03-27T09:27:59Z
dc.date.issued2020en
dc.identifier.citationGelderblom H, Jones RL, George S, Valverde Morales C, Benson C, Jean-Yves B, et al. Imatinib in combination with phosphoinositol kinase inhibitor buparlisib in patients with gastrointestinal stromal tumour who failed prior therapy with imatinib and sunitinib: a Phase 1b, multicentre study. Br J Cancer. 2020.en
dc.identifier.pmid32147671en
dc.identifier.doi10.1038/s41416-020-0769-yen
dc.identifier.urihttp://hdl.handle.net/10541/622817
dc.description.abstractBACKGROUND: The majority of patients with advanced gastrointestinal stromal tumours (GISTs) develop resistance to imatinib and sunitinib, the standard of care for these patients. This study evaluated the combination of buparlisib, an oral phosphoinositide 3-kinase (PI3K) inhibitor, with imatinib in patients with advanced GIST, who have failed prior therapy with imatinib and sunitinib. METHODS: This Phase 1b, multicentre, open-label study aimed to determine the maximum tolerated dose (MTD) and/or a recommended Phase 2 dose of buparlisib in combination with 400 mg of imatinib through a dose-escalation part and a dose-expansion part, and also evaluated the clinical profile of the combination. RESULTS: Sixty patients were enrolled, including 25 in the dose-escalation part and 35 in the dose-expansion part. In the combination, MTD of buparlisib was established as 80 mg. No partial or complete responses were observed. The estimated median progression-free survival was 3.5 months in the expansion phase. Overall, 98.3% of patients had treatment-related adverse events (AEs), including 45% with grade 3 or 4 AEs. CONCLUSIONS: Buparlisib in combination with imatinib provided no additional benefit compared with currently available therapies. Due to the lack of objective responses, further development of this combination was not pursued for third-line/fourth-line advanced/metastatic GIST.en
dc.language.isoenen
dc.relation.urlhttps://dx.doi.org/10.1038/s41416-020-0769-yen
dc.titleImatinib in combination with phosphoinositol kinase inhibitor buparlisib in patients with gastrointestinal stromal tumour who failed prior therapy with imatinib and sunitinib: a Phase 1b, multicentre studyen
dc.typeArticleen
dc.contributor.departmentLeiden University Medical Center, Leiden, The Netherlands.en
dc.identifier.journalBritish Journal of Canceren
dc.description.noteen]


This item appears in the following Collection(s)

Show simple item record